2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.12A.32 Discontinuation of EGFR-TKI in NSCLC During COVID-19 Infection: Assessing Unvaccination, Low BMI, and Comorbidities

EP.12A.32 Discontinuation of EGFR-TKI in NSCLC During COVID-19 Infection: Assessing Unvaccination, Low BMI, and Comorbidities

Back to course

Pdf Summary

The retrospective study by Huang et al. focuses on the impact of COVID-19 infection on patients with non-small-cell lung cancer (NSCLC) who are undergoing treatment with EGFR-TKI (epidermal growth factor receptor tyrosine kinase inhibitors). The research aims to assess how factors such as vaccination status, body mass index (BMI), and comorbidities influence the hospitalization and prognosis of these patients during the pandemic.<br /><br />The study found that NSCLC patients who had not received a COVID-19 vaccination, had a BMI of less than 22.3 kg/m², and had comorbidities experienced higher rates of infection and hospitalization compared to those who were vaccinated, had a higher BMI, and no comorbid conditions. The results suggest that continuing EGFR-TKI treatment in unvaccinated patients with low BMI and comorbidities during the active phase of COVID-19 infection poses increased risks to patient survival.<br /><br />Based on these observations, the study concludes that treatment continuation is feasible for vaccinated patients with higher BMI and no comorbidities. However, treatment suspension should be considered for those in the active infection phase to mitigate risks. Importantly, the study underscores the necessity of identifying patients at high risk for serious outcomes early on. Additionally, it suggests that the interaction between SARS-CoV-2 infection and EGFR mutation in NSCLC patients undergoing TKI therapy requires further exploration to guide future clinical decisions.<br /><br />The research acknowledges contributions by other investigators and relies on previous studies highlighting the implications of COVID-19 on cancer treatment and outcomes.<br /><br />In summary, this study provides essential insights into managing NSCLC patients treated with EGFR-TKI during the COVID-19 pandemic, emphasizing the importance of vaccination, weight management, and the absence of comorbidities in improving patient outcomes.

Asset Subtitle

Peng Huang

Meta Tag

Speaker Peng Huang

Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy

Keywords

COVID-19

non-small-cell lung cancer

NSCLC

EGFR-TKI

vaccination

body mass index

BMI

comorbidities

hospitalization

prognosis